Financings Of The Fortnight: Third Rock Bets Big on Global Blood Therapeutics’ Allosteric Modulators
This article was originally published in The Pink Sheet Daily
Plus news on recent financial activity by Igenica, PhaseBio Pharmaceuticals, Seldar Pharmaceuticals and BioMarin Pharmaceutical.
You may also be interested in...
GBT440 is not efficacious enough in studies of idiopathic pulmonary fibrosis, but the drug was well-tolerated at twice the exposure in the treatment of sickle cell disease, the drug's lead indication.
In the firm’s largest solo investment ever, Third Rock backed a new platform company that will seek to identify and develop a pipeline of drugs for rare blood disorders.
The Endocrinologic and Metabolic Drugs Advisory Committee votes 18-4, with one abstention, in favor of lorcaserin for long-term treatment of overweight and obese individuals.